BKE heads into its May 22 earnings report with a striking divergence: the stock is up 15% over the past month, yet insiders have been consistent sellers and short interest has climbed to its highest level since at least mid-March.
The insider picture is the clearest signal right now. Two senior executives — EVP Kari Smith and SVP Michelle Hoffman — sold a combined $6.5m of stock in the 90 days through April 10, with the most recent trades hitting on April 10 at prices around $54.55–$54.80. Smith alone sold nearly 80,000 shares across three separate transactions since mid-March. That kind of clustered, multi-week selling by two named executives into a rising tape is the kind of activity worth tracking closely into the Q1 print.
Short positioning backs up the cautious read. Short interest has climbed from roughly 9.8% of the free float in mid-March to 11.7% by April 28 — a rise of almost two percentage points in six weeks — driven largely by a step-change higher in early April. The FINRA fortnightly figure puts official short interest at around 3.74m shares, with days-to-cover near 8.9 — a level that would take the better part of two weeks to unwind at average volumes. Availability remains extremely loose, however, with borrow rates at just 0.31% APR. That means there is no pressure on short sellers from the lending market — they can maintain and add to positions cheaply. The borrow rate has actually eased about 26% over the past week after some mid-month volatility, reinforcing how low the friction is for shorts.
Options are a different story. The put/call ratio has drifted below its 20-day average, running at 0.91 versus a mean of 0.96 — about 1.2 standard deviations below average. That points to relatively modest demand for downside protection despite the building short book. Calls are the more active side of the market right now. That divergence between options positioning and the rising short interest is the most interesting tension in the setup: shorts are adding, but options traders aren't yet hedging defensively.
The analyst picture adds more caution. UBS Neutral-rated the stock with a $53 target as of mid-March — roughly 6% below the current price of $56.53 — after trimming the target from $55. With the stock now trading through the stated target, the Street consensus effectively sits in bear territory on valuation. The EPS surprise score ranks in the 69th percentile and the dividend factor ranks at 73, so the fundamental quality backdrop is decent. But the valuation setup — a trailing PE of roughly 14.5x, price-to-book near 4.4x, and EV/EBITDA around 10.4x — has crept higher on the 14% monthly price move, and the lone active analyst has not followed the stock up.
Among correlated peers, BKE's 1.5% gain on the week compares favourably to WSM (down 7.4%), VSCO (down 5.8%), and CAL (down 3.0%), while BOOT moved roughly in line at +1.8%. The relative outperformance against sector peers makes the insider selling more notable — executives have been distributing shares at precisely the moment the stock was printing its strongest relative returns.
The May 22 earnings call is now the focal point. At the last report in March, the stock fell 2.6% the next day and was off 2.9% five days later — a modest but consistent negative reaction. With short interest at a six-week high, insider sellers active into the rally, and the UBS target already below market, the setup heading into that print is more layered than the price chart alone suggests.
See the live data behind this article on ORTEX.
Open BKE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
